Skip to content
value.today

Manhattan Pharmaceuticals Inc.

Total raised
$11 M
1 round on record
Latest round
$11 M
Dec 2011
First round on record
Dec 2011
Today
Went public
See the company page

Manhattan Pharmaceuticals Inc. is listed today as TG Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Manhattan Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2011$11 MNo. 1$10 to $50 million

Manhattan Pharmaceuticals Inc.: Raise no. 1, Dec 2011

Investors in this round

0 investors had bought by the notice of Mar 26, 2012: 0 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Manhattan Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $25 M offered; $14 M still to sell
Smallest investment taken
$50,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$25,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Weiss · Executive Officer, Director
  • Sean Power · Executive Officer
  • Neil Herskowitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation · Seattle, WashingtonSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, IL, IN, KS, LA, MA, MD, MI, MN, MO, MS, NC, NE, NH, NJ, NM, NV, NY, OH, OR, PA, RI, TN, TX, UT, VA, WA, WI

Remarks in the notice

  • On the amounts: “The offering includes securities to be acquired upon the exercise or exchange of other securities.”

Signed by Sean Power, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D and 2 amendments, newest notice filed Mar 26, 2012. Read the notice at the SEC.

equity, optionsSEC
Mar 2010$3 MIssued in a merger or acquisition$2 to $10 million

Manhattan Pharmaceuticals Inc.: Private sale, Mar 2010

Investors in this round

77 investors had bought by the notice of Mar 16, 2010: 77 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Manhattan Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
$5,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
  • 46
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$400,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael McGuinness · Executive Officer
  • Douglas Abel · Director
  • Neil Herskowitz · Director
  • Richard Steinhart · Director
  • Timothy McInerney · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · New York, NySold in no state named

Signed by Michael McGuinness, COO and CFO. Source: SEC Form D, newest notice filed Mar 16, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company TG Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: License $9.36 million (2%), Royalty $5.62 million (1%), Other Revenue $3.59 million (1%), License Revenue $150,000 (0%).

    Annual report (SEC XBRL) · Dec 2025

  • Manhattan Pharmaceuticals Inc. had no revenue when it filed its newest notice of a funding round (Mar 2012).

    SEC Form D (revenue range) · Mar 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2012

Products and services#

No products or services of Manhattan Pharmaceuticals Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Manhattan Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Michael S. WeissPersonnot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2012)SEC Form 3
Opus Point Partners, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Sean A. PowerPersonnot statednot statedHeld Series A preferred stock (Form 3, 2012)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 0 investors.

Largest shareholders today

Institutions holding TG Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Manhattan Pharmaceuticals Inc.
NameRoleNamed in
Michael WeissExecutive officerMar 2012
Sean PowerExecutive officerMar 2012
Michael McGuinnessExecutive officerMar 2010
Michael WeissDirectorMar 2012
Neil HerskowitzDirectorMar 2012
Douglas AbelDirectorMar 2010
Richard SteinhartDirectorMar 2010
Timothy McInerneyDirectorMar 2010

About

A commercial stage biopharmaceutical company.

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.